ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neuroprotective Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-16P7533
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Neuroprotective Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Global Neuroprotective Drugs Market Research Report 2025

Code: QYRE-Auto-16P7533
Report
September 2025
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Genervon
Neurovive Pharmaceutical
Ceregene
BHR Pharma
Neuren Pharmaceuticals
Allon Therapeutics
Bionure
Astrazeneca plc
Biogen
Merck KGaA
Teva Pharmaceutical Industries Ltd
Novartis

Neuroprotective Drugs Market

The global market for Neuroprotective Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions. 
Factors expected to drive market growth include increasing prevalence of neurological disorders. Neurological diseases are the leading cause of disability and death worldwide. The “big three” neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, have resulted in significant increases in morbidity and mortality in the elderly population worldwide. Neuroprotective drugs are those that help maintain the structure and function of neurons. Neuroprotective drugs have the potential to reduce stroke deaths by 6 million per year. According to data updated by the World Health Organization in February 2022, approximately 50 million people worldwide suffer from epilepsy every year.
Alzheimer"s disease segment is expected to hold major market share in the neuroprotective agents market
The incidence of Alzheimer"s disease has been increasing and is expected to continue to increase in the coming decades. According to statistics from the World Health Organization, nearly 50 million people worldwide were suffering from Alzheimer"s disease and other dementias in 2020, and this number is expected to exceed 152 million by 2050. Additionally, Alzheimer"s disease progression increases with age and is the fifth largest contributor to the global disease burden, with the global disease burden exceeding 1 Trillions of dollars.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neuroprotective Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroprotective Drugs.
The Neuroprotective Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuroprotective Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuroprotective Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Neuroprotective Drugs Market Report

Report Metric Details
Report Name Neuroprotective Drugs Market
Segment by Type
  • Cholinesterase inhibitors
  • Anti-inflammatory
  • Others
Segment by Application
  • Alzheimer's disease
  • Parkinson's disease
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Genervon, NeuroVive Pharmaceutical, Ceregene, BHR Pharma, Neuren Pharmaceuticals, Allon therapeutics, Bionure, AstraZeneca, Biogen, Merck KGaA, Teva Pharmaceutical Industries Ltd, Novartis
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Neuroprotective Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Neuroprotective Drugs Market report?

Ans: The main players in the Neuroprotective Drugs Market are Genervon, NeuroVive Pharmaceutical, Ceregene, BHR Pharma, Neuren Pharmaceuticals, Allon therapeutics, Bionure, AstraZeneca, Biogen, Merck KGaA, Teva Pharmaceutical Industries Ltd, Novartis

What are the Application segmentation covered in the Neuroprotective Drugs Market report?

Ans: The Applications covered in the Neuroprotective Drugs Market report are Alzheimer's disease, Parkinson's disease, Others

What are the Type segmentation covered in the Neuroprotective Drugs Market report?

Ans: The Types covered in the Neuroprotective Drugs Market report are Cholinesterase inhibitors, Anti-inflammatory, Others

1 Neuroprotective Drugs Market Overview
1.1 Product Definition
1.2 Neuroprotective Drugs by Type
1.2.1 Global Neuroprotective Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Cholinesterase inhibitors
1.2.3 Anti-inflammatory
1.2.4 Others
1.3 Neuroprotective Drugs by Application
1.3.1 Global Neuroprotective Drugs Market Value by Application (2024 VS 2031)
1.3.2 Alzheimer's disease
1.3.3 Parkinson's disease
1.3.4 Others
1.4 Global Neuroprotective Drugs Market Size Estimates and Forecasts
1.4.1 Global Neuroprotective Drugs Revenue 2020-2031
1.4.2 Global Neuroprotective Drugs Sales 2020-2031
1.4.3 Global Neuroprotective Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Neuroprotective Drugs Market Competition by Manufacturers
2.1 Global Neuroprotective Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Neuroprotective Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Neuroprotective Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Neuroprotective Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neuroprotective Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neuroprotective Drugs, Product Type & Application
2.7 Global Key Manufacturers of Neuroprotective Drugs, Date of Enter into This Industry
2.8 Global Neuroprotective Drugs Market Competitive Situation and Trends
2.8.1 Global Neuroprotective Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Neuroprotective Drugs Players Market Share by Revenue
2.8.3 Global Neuroprotective Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neuroprotective Drugs Market Scenario by Region
3.1 Global Neuroprotective Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Neuroprotective Drugs Sales by Region: 2020-2031
3.2.1 Global Neuroprotective Drugs Sales by Region: 2020-2025
3.2.2 Global Neuroprotective Drugs Sales by Region: 2026-2031
3.3 Global Neuroprotective Drugs Revenue by Region: 2020-2031
3.3.1 Global Neuroprotective Drugs Revenue by Region: 2020-2025
3.3.2 Global Neuroprotective Drugs Revenue by Region: 2026-2031
3.4 North America Neuroprotective Drugs Market Facts & Figures by Country
3.4.1 North America Neuroprotective Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Neuroprotective Drugs Sales by Country (2020-2031)
3.4.3 North America Neuroprotective Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neuroprotective Drugs Market Facts & Figures by Country
3.5.1 Europe Neuroprotective Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Neuroprotective Drugs Sales by Country (2020-2031)
3.5.3 Europe Neuroprotective Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neuroprotective Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Neuroprotective Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Neuroprotective Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Neuroprotective Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neuroprotective Drugs Market Facts & Figures by Country
3.7.1 Latin America Neuroprotective Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Neuroprotective Drugs Sales by Country (2020-2031)
3.7.3 Latin America Neuroprotective Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neuroprotective Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Neuroprotective Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Neuroprotective Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Neuroprotective Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Neuroprotective Drugs Sales by Type (2020-2031)
4.1.1 Global Neuroprotective Drugs Sales by Type (2020-2025)
4.1.2 Global Neuroprotective Drugs Sales by Type (2026-2031)
4.1.3 Global Neuroprotective Drugs Sales Market Share by Type (2020-2031)
4.2 Global Neuroprotective Drugs Revenue by Type (2020-2031)
4.2.1 Global Neuroprotective Drugs Revenue by Type (2020-2025)
4.2.2 Global Neuroprotective Drugs Revenue by Type (2026-2031)
4.2.3 Global Neuroprotective Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Neuroprotective Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Neuroprotective Drugs Sales by Application (2020-2031)
5.1.1 Global Neuroprotective Drugs Sales by Application (2020-2025)
5.1.2 Global Neuroprotective Drugs Sales by Application (2026-2031)
5.1.3 Global Neuroprotective Drugs Sales Market Share by Application (2020-2031)
5.2 Global Neuroprotective Drugs Revenue by Application (2020-2031)
5.2.1 Global Neuroprotective Drugs Revenue by Application (2020-2025)
5.2.2 Global Neuroprotective Drugs Revenue by Application (2026-2031)
5.2.3 Global Neuroprotective Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Neuroprotective Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Genervon
6.1.1 Genervon Company Information
6.1.2 Genervon Description and Business Overview
6.1.3 Genervon Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Genervon Neuroprotective Drugs Product Portfolio
6.1.5 Genervon Recent Developments/Updates
6.2 NeuroVive Pharmaceutical
6.2.1 NeuroVive Pharmaceutical Company Information
6.2.2 NeuroVive Pharmaceutical Description and Business Overview
6.2.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolio
6.2.5 NeuroVive Pharmaceutical Recent Developments/Updates
6.3 Ceregene
6.3.1 Ceregene Company Information
6.3.2 Ceregene Description and Business Overview
6.3.3 Ceregene Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Ceregene Neuroprotective Drugs Product Portfolio
6.3.5 Ceregene Recent Developments/Updates
6.4 BHR Pharma
6.4.1 BHR Pharma Company Information
6.4.2 BHR Pharma Description and Business Overview
6.4.3 BHR Pharma Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 BHR Pharma Neuroprotective Drugs Product Portfolio
6.4.5 BHR Pharma Recent Developments/Updates
6.5 Neuren Pharmaceuticals
6.5.1 Neuren Pharmaceuticals Company Information
6.5.2 Neuren Pharmaceuticals Description and Business Overview
6.5.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolio
6.5.5 Neuren Pharmaceuticals Recent Developments/Updates
6.6 Allon therapeutics
6.6.1 Allon therapeutics Company Information
6.6.2 Allon therapeutics Description and Business Overview
6.6.3 Allon therapeutics Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Allon therapeutics Neuroprotective Drugs Product Portfolio
6.6.5 Allon therapeutics Recent Developments/Updates
6.7 Bionure
6.7.1 Bionure Company Information
6.7.2 Bionure Description and Business Overview
6.7.3 Bionure Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bionure Neuroprotective Drugs Product Portfolio
6.7.5 Bionure Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Company Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 AstraZeneca Neuroprotective Drugs Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Biogen
6.9.1 Biogen Company Information
6.9.2 Biogen Description and Business Overview
6.9.3 Biogen Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Biogen Neuroprotective Drugs Product Portfolio
6.9.5 Biogen Recent Developments/Updates
6.10 Merck KGaA
6.10.1 Merck KGaA Company Information
6.10.2 Merck KGaA Description and Business Overview
6.10.3 Merck KGaA Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Merck KGaA Neuroprotective Drugs Product Portfolio
6.10.5 Merck KGaA Recent Developments/Updates
6.11 Teva Pharmaceutical Industries Ltd
6.11.1 Teva Pharmaceutical Industries Ltd Company Information
6.11.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.11.3 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolio
6.11.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.12 Novartis
6.12.1 Novartis Company Information
6.12.2 Novartis Description and Business Overview
6.12.3 Novartis Neuroprotective Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Novartis Neuroprotective Drugs Product Portfolio
6.12.5 Novartis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neuroprotective Drugs Industry Chain Analysis
7.2 Neuroprotective Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neuroprotective Drugs Production Mode & Process Analysis
7.4 Neuroprotective Drugs Sales and Marketing
7.4.1 Neuroprotective Drugs Sales Channels
7.4.2 Neuroprotective Drugs Distributors
7.5 Neuroprotective Drugs Customer Analysis
8 Neuroprotective Drugs Market Dynamics
8.1 Neuroprotective Drugs Industry Trends
8.2 Neuroprotective Drugs Market Drivers
8.3 Neuroprotective Drugs Market Challenges
8.4 Neuroprotective Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Genervon
Neurovive Pharmaceutical
Ceregene
BHR Pharma
Neuren Pharmaceuticals
Allon Therapeutics
Bionure
Astrazeneca plc
Biogen
Merck KGaA
Teva Pharmaceutical Industries Ltd
Novartis
List of Tables
 Table 1. Global Neuroprotective Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Neuroprotective Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Neuroprotective Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Neuroprotective Drugs Sales (MT) of Key Manufacturers (2020-2025)
 Table 5. Global Neuroprotective Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Neuroprotective Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Neuroprotective Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Neuroprotective Drugs Average Price (USD/Kg) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Neuroprotective Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Neuroprotective Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Neuroprotective Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Neuroprotective Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Neuroprotective Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroprotective Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Neuroprotective Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Neuroprotective Drugs Sales by Region (2020-2025) & (MT)
 Table 18. Global Neuroprotective Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Neuroprotective Drugs Sales by Region (2026-2031) & (MT)
 Table 20. Global Neuroprotective Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Neuroprotective Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Neuroprotective Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Neuroprotective Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Neuroprotective Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Neuroprotective Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
 Table 27. North America Neuroprotective Drugs Sales by Country (2026-2031) & (MT)
 Table 28. North America Neuroprotective Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Neuroprotective Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Neuroprotective Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
 Table 32. Europe Neuroprotective Drugs Sales by Country (2026-2031) & (MT)
 Table 33. Europe Neuroprotective Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Neuroprotective Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Neuroprotective Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Neuroprotective Drugs Sales by Region (2020-2025) & (MT)
 Table 37. Asia Pacific Neuroprotective Drugs Sales by Region (2026-2031) & (MT)
 Table 38. Asia Pacific Neuroprotective Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Neuroprotective Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Neuroprotective Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
 Table 42. Latin America Neuroprotective Drugs Sales by Country (2026-2031) & (MT)
 Table 43. Latin America Neuroprotective Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Neuroprotective Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Neuroprotective Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
 Table 47. Middle East and Africa Neuroprotective Drugs Sales by Country (2026-2031) & (MT)
 Table 48. Middle East and Africa Neuroprotective Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Neuroprotective Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Neuroprotective Drugs Sales (MT) by Type (2020-2025)
 Table 51. Global Neuroprotective Drugs Sales (MT) by Type (2026-2031)
 Table 52. Global Neuroprotective Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Neuroprotective Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Neuroprotective Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Neuroprotective Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Neuroprotective Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Neuroprotective Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Neuroprotective Drugs Price (USD/Kg) by Type (2020-2025)
 Table 59. Global Neuroprotective Drugs Price (USD/Kg) by Type (2026-2031)
 Table 60. Global Neuroprotective Drugs Sales (MT) by Application (2020-2025)
 Table 61. Global Neuroprotective Drugs Sales (MT) by Application (2026-2031)
 Table 62. Global Neuroprotective Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Neuroprotective Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Neuroprotective Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Neuroprotective Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Neuroprotective Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Neuroprotective Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Neuroprotective Drugs Price (USD/Kg) by Application (2020-2025)
 Table 69. Global Neuroprotective Drugs Price (USD/Kg) by Application (2026-2031)
 Table 70. Genervon Company Information
 Table 71. Genervon Description and Business Overview
 Table 72. Genervon Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 73. Genervon Neuroprotective Drugs Product
 Table 74. Genervon Recent Developments/Updates
 Table 75. NeuroVive Pharmaceutical Company Information
 Table 76. NeuroVive Pharmaceutical Description and Business Overview
 Table 77. NeuroVive Pharmaceutical Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 78. NeuroVive Pharmaceutical Neuroprotective Drugs Product
 Table 79. NeuroVive Pharmaceutical Recent Developments/Updates
 Table 80. Ceregene Company Information
 Table 81. Ceregene Description and Business Overview
 Table 82. Ceregene Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 83. Ceregene Neuroprotective Drugs Product
 Table 84. Ceregene Recent Developments/Updates
 Table 85. BHR Pharma Company Information
 Table 86. BHR Pharma Description and Business Overview
 Table 87. BHR Pharma Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 88. BHR Pharma Neuroprotective Drugs Product
 Table 89. BHR Pharma Recent Developments/Updates
 Table 90. Neuren Pharmaceuticals Company Information
 Table 91. Neuren Pharmaceuticals Description and Business Overview
 Table 92. Neuren Pharmaceuticals Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 93. Neuren Pharmaceuticals Neuroprotective Drugs Product
 Table 94. Neuren Pharmaceuticals Recent Developments/Updates
 Table 95. Allon therapeutics Company Information
 Table 96. Allon therapeutics Description and Business Overview
 Table 97. Allon therapeutics Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 98. Allon therapeutics Neuroprotective Drugs Product
 Table 99. Allon therapeutics Recent Developments/Updates
 Table 100. Bionure Company Information
 Table 101. Bionure Description and Business Overview
 Table 102. Bionure Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 103. Bionure Neuroprotective Drugs Product
 Table 104. Bionure Recent Developments/Updates
 Table 105. AstraZeneca Company Information
 Table 106. AstraZeneca Description and Business Overview
 Table 107. AstraZeneca Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 108. AstraZeneca Neuroprotective Drugs Product
 Table 109. AstraZeneca Recent Developments/Updates
 Table 110. Biogen Company Information
 Table 111. Biogen Description and Business Overview
 Table 112. Biogen Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 113. Biogen Neuroprotective Drugs Product
 Table 114. Biogen Recent Developments/Updates
 Table 115. Merck KGaA Company Information
 Table 116. Merck KGaA Description and Business Overview
 Table 117. Merck KGaA Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 118. Merck KGaA Neuroprotective Drugs Product
 Table 119. Merck KGaA Recent Developments/Updates
 Table 120. Teva Pharmaceutical Industries Ltd Company Information
 Table 121. Teva Pharmaceutical Industries Ltd Description and Business Overview
 Table 122. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 123. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product
 Table 124. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
 Table 125. Novartis Company Information
 Table 126. Novartis Description and Business Overview
 Table 127. Novartis Neuroprotective Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 128. Novartis Neuroprotective Drugs Product
 Table 129. Novartis Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Neuroprotective Drugs Distributors List
 Table 133. Neuroprotective Drugs Customers List
 Table 134. Neuroprotective Drugs Market Trends
 Table 135. Neuroprotective Drugs Market Drivers
 Table 136. Neuroprotective Drugs Market Challenges
 Table 137. Neuroprotective Drugs Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Neuroprotective Drugs
 Figure 2. Global Neuroprotective Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neuroprotective Drugs Market Share by Type: 2024 & 2031
 Figure 4. Cholinesterase inhibitors Product Picture
 Figure 5. Anti-inflammatory Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Neuroprotective Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Neuroprotective Drugs Market Share by Application: 2024 & 2031
 Figure 9. Alzheimer's disease
 Figure 10. Parkinson's disease
 Figure 11. Others
 Figure 12. Global Neuroprotective Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Neuroprotective Drugs Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Neuroprotective Drugs Sales (2020-2031) & (MT)
 Figure 15. Global Neuroprotective Drugs Average Price (USD/Kg) & (2020-2031)
 Figure 16. Neuroprotective Drugs Report Years Considered
 Figure 17. Neuroprotective Drugs Sales Share by Manufacturers in 2024
 Figure 18. Global Neuroprotective Drugs Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Neuroprotective Drugs Players: Market Share by Revenue in Neuroprotective Drugs in 2024
 Figure 20. Neuroprotective Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Neuroprotective Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Neuroprotective Drugs Sales Market Share by Country (2020-2031)
 Figure 23. North America Neuroprotective Drugs Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Neuroprotective Drugs Sales Market Share by Country (2020-2031)
 Figure 27. Europe Neuroprotective Drugs Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Neuroprotective Drugs Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Neuroprotective Drugs Revenue Market Share by Region (2020-2031)
 Figure 35. China Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Neuroprotective Drugs Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Neuroprotective Drugs Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Neuroprotective Drugs Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Neuroprotective Drugs Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. U.A.E Neuroprotective Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Neuroprotective Drugs by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Neuroprotective Drugs by Type (2020-2031)
 Figure 57. Global Neuroprotective Drugs Price (USD/Kg) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Neuroprotective Drugs by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Neuroprotective Drugs by Application (2020-2031)
 Figure 60. Global Neuroprotective Drugs Price (USD/Kg) by Application (2020-2031)
 Figure 61. Neuroprotective Drugs Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Neuroprotective Products Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neuroprotective Agents Market Insights Forecast to 2030
Neuroprotection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Nervous System Chemicals Market Research Report 2024
Global Anti dementia Drugs Market Research Report 2024
Global Neurodegenerative Disorder Therapeutics Market Research Report 2024
Global Memory Enhancing Drug Market Insights Forecast to 2030
Global Neurodegenerative Disease Treatment Market Research Report 2024
Global Drugs for Central Nervous System Diseases Market Insights Forecast to 2030
Global Neurosurgery Drug Market Research Report 2025
Neurodegenerative Diseases Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Memory Enhancement Drugs Market Insights Forecast to 2030
Anti Ageing Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Alzheimer Treatment Drug Market Research Report 2025
Global Neuroleptic Market Research Report 2025
Global Regenerative Drugs Market Insights Forecast to 2030
Global Neurological Devices Market Research Report 2024
Global Epilepsy Treatment Drug Market Research Report 2024
Global Neuropathic Pain Drugs Market Research Report 2024
Global Cerebroprotein Hydrolysate Drug Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions